免疫调节剂在预防和抑制炎症性肠病中抗肿瘤坏死因子治疗的抗药抗体方面的疗效。
The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease.
作者信息
Fousekis Fotios S, Papamichael Konstantinos, Kourtis Georgios, Albani Eleni N, Orfanidou Afroditi, Saridi Maria, Katsanos Konstantinos H, Christodoulou Dimitrios K
机构信息
Department of Gastroenterology, School of Health Sciences, University Hospital of Ioannina, Faculty of Medicine, University of Ioannina, Ioannina, Greece (Fotios S. Fousekis, Konstantinos H. Katsanos, Dimitrios K. Christodoulou).
Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA (Konstantinos Papamichael).
出版信息
Ann Gastroenterol. 2022 Jan-Feb;35(1):1-7. doi: 10.20524/aog.2021.0682. Epub 2021 Dec 6.
Abstract
The development of biological agents against tumor necrosis factor (TNF) has revolutionized the management of inflammatory bowel disease (IBD), frequently achieving induction and maintenance of remission in both ulcerative colitis and Crohn's disease. However, a loss of response due to the development of anti-drug antibodies (ADA) is seen annually in approximately 20% of IBD patients receiving anti-TNF therapy. Current evidence suggests that the use of immunomodulators (IMM), such as thiopurines (azathioprine and 6-mercaptopurine) or methotrexate, may prevent or suppress ADA formation. In this article, we present a comprehensive review of the available literature regarding the efficacy of IMM in the prevention and suppression of ADA development to anti-TNF therapy in patients with IBD.
摘要
抗肿瘤坏死因子（TNF）生物制剂的研发彻底改变了炎症性肠病（IBD）的治疗方式，在溃疡性结肠炎和克罗恩病中常常能够实现缓解的诱导和维持。然而，每年约20%接受抗TNF治疗的IBD患者会因产生抗药物抗体（ADA）而出现应答丧失。目前的证据表明，使用免疫调节剂（IMM），如硫唑嘌呤（硫唑嘌呤和6-巯基嘌呤）或甲氨蝶呤，可能预防或抑制ADA的形成。在本文中，我们对现有文献进行了全面综述，内容涉及IMM在预防和抑制IBD患者抗TNF治疗中ADA产生方面的疗效。
相似文献
1
The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease.免疫调节剂在预防和抑制炎症性肠病中抗肿瘤坏死因子治疗的抗药抗体方面的疗效。
Ann Gastroenterol. 2022 Jan-Feb;35(1):1-7. doi: 10.20524/aog.2021.0682. Epub 2021 Dec 6.
2
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
3
Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis.添加免疫调节剂逆转抗肿瘤坏死因子抑制剂的抗药物抗体：一项系统评价和荟萃分析。
Indian J Gastroenterol. 2020 Apr;39(2):153-160. doi: 10.1007/s12664-020-01031-0. Epub 2020 May 28.
4
Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.硫嘌呤类药物与炎症性肠病：当前证据及历史视角
World J Gastroenterol. 2016 Dec 14;22(46):10103-10117. doi: 10.3748/wjg.v22.i46.10103.
5
Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.炎症性肠病患者针对抗 TNF 的抗药物抗体：可能策略的评估。
Scand J Gastroenterol. 2024 Jan-Jun;59(2):169-175. doi: 10.1080/00365521.2023.2278424. Epub 2024 Jan 30.
6
Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.硫嘌呤类药物和甲氨蝶呤在炎症性肠病中的应用进展
Curr Gastroenterol Rep. 2018 Sep 28;20(11):53. doi: 10.1007/s11894-018-0658-1.
7
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病：英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
8
Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era.生物制剂时代炎症性肠病患者使用硫嘌呤和甲氨蝶呤的情况
Curr Treat Options Gastroenterol. 2017 Mar;15(1):84-104. doi: 10.1007/s11938-017-0128-0.
9
Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.免疫调节剂联合治疗对炎症性肠病患者肿瘤坏死因子拮抗剂的谷浓度和抗体的影响：一项荟萃分析。
Clin Gastroenterol Hepatol. 2017 Sep;15(9):1359-1372.e6. doi: 10.1016/j.cgh.2017.02.005. Epub 2017 Feb 14.
10
Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis.生物单药疗法与免疫调节剂联合疗法在克罗恩病和溃疡性结肠炎缓解诱导及维持中的应用
Ann Gastroenterol. 2021 Sep-Oct;34(5):612-624. doi: 10.20524/aog.2021.0645. Epub 2021 Jun 14.
引用本文的文献
1
The Durability of Anti-TNF Therapy for Crohn's Disease Is Higher in Anti-TNF Naïve Patients and Increases With Proactive Therapeutic Drug Monitoring.抗肿瘤坏死因子（TNF）治疗对克罗恩病的持久性在未使用过TNF治疗的患者中更高，且随着主动治疗药物监测而增加。
Crohns Colitis 360. 2025 Apr 9;7(2):otaf028. doi: 10.1093/crocol/otaf028. eCollection 2025 Apr.
2
Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease-Reports from a Romanian Center.罗马尼亚某中心关于抗肿瘤坏死因子-α在儿童炎症性肠病中的应用报告
Pharmaceuticals (Basel). 2025 Jan 11;18(1):84. doi: 10.3390/ph18010084.
3
Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United States.结节病性神经病变管理的共识性建议：一项针对美国各地专家的德尔菲调查
Neurol Clin Pract. 2025 Apr;15(2):e200429. doi: 10.1212/CPJ.0000000000200429. Epub 2025 Jan 15.
4
Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China.炎症性肠病双靶点治疗的疗效与安全性：一项中国的回顾性多中心研究
Therap Adv Gastroenterol. 2025 Jan 2;18:17562848241307598. doi: 10.1177/17562848241307598. eCollection 2025.
5
Infliximab trough levels among patients with inflammatory bowel disease in correlation with infliximab treatment escalation: a cross-sectional study from a Greek tertiary center.希腊三级中心的一项横断面研究：炎症性肠病患者英夫利昔单抗谷浓度与英夫利昔单抗治疗升级的相关性
Ann Gastroenterol. 2024 Nov-Dec;37(6):674-681. doi: 10.20524/aog.2024.0926. Epub 2024 Oct 31.
6
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.用于炎症性肠病的治疗性抗体的免疫原性：治疗与临床考量
Drugs. 2025 Jan;85(1):67-85. doi: 10.1007/s40265-024-02115-3. Epub 2024 Nov 13.
7
Phytochemical Compounds as Promising Therapeutics for Intestinal Fibrosis in Inflammatory Bowel Disease: A Critical Review.植物化学物质作为炎症性肠病中肠纤维化的有前途的治疗方法：批判性评价。
Nutrients. 2024 Oct 25;16(21):3633. doi: 10.3390/nu16213633.
8
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.溃疡性结肠炎连续治疗152周后mirikizumab的三年疗效和安全性：LUCENT-3开放标签扩展研究结果
Inflamm Bowel Dis. 2024 Oct 25. doi: 10.1093/ibd/izae253.
9
Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis.在英夫利昔单抗单药治疗中添加反应性免疫调节剂可恢复炎症性肠病的临床反应：一项荟萃分析。
Dig Dis Sci. 2024 Oct;69(10):3920-3931. doi: 10.1007/s10620-024-08515-5. Epub 2024 Jun 14.
10
Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn's Disease: A Pilot Study.甲氨蝶呤联合英夫利昔单抗初始治疗小儿克罗恩病的疗效：一项初步研究。
Biomedicines. 2023 Sep 19;11(9):2575. doi: 10.3390/biomedicines11092575.
本文引用的文献
1
Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction.英夫利昔单抗重新引入期间主动治疗药物监测的真实世界经验
Crohns Colitis 360. 2021 Jul 13;3(3):otab048. doi: 10.1093/crocol/otab048. eCollection 2021 Jul.
2
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.BI 695501 对比阿达木单抗参比制剂治疗中重度克罗恩病患者的安全性和疗效（VOLTAIRE-CD）：一项多中心、随机、双盲、3 期临床试验。
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):816-825. doi: 10.1016/S2468-1253(21)00252-1. Epub 2021 Aug 11.
3
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.炎症性肠病生物制剂治疗药物监测的全面文献回顾和专家共识声明。
Am J Gastroenterol. 2021 Oct 1;116(10):2014-2025. doi: 10.14309/ajg.0000000000001396.
4
A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence.英夫利昔单抗生物类似药SB2的系统评价：从临床前数据到真实世界证据
Expert Opin Biol Ther. 2022 Feb;22(2):203-223. doi: 10.1080/14712598.2021.1958778.
5
Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis.抗 TNF 和免疫抑制联合治疗在诱导活动期炎症性肠病患者临床缓解方面更具优势：系统评价和荟萃分析。
J Dig Dis. 2021 Jul;22(7):408-418. doi: 10.1111/1751-2980.13026. Epub 2021 Jun 29.
6
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.从原研英夫利昔单抗转换后，生物类似药SB2在炎症性肠病患者中的长期有效性、安全性和免疫原性。
Therap Adv Gastroenterol. 2021 Jan 14;14:1756284820982802. doi: 10.1177/1756284820982802. eCollection 2021.
7
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.抗 TNF 治疗炎症性肠病 25 年：回顾过去，展望未来。
Gut. 2021 Jul;70(7):1396-1405. doi: 10.1136/gutjnl-2019-320022. Epub 2021 Jan 11.
8
Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.药物水平较低或对先前抗肿瘤坏死因子产生抗体的患者更有可能对后续的抗肿瘤坏死因子产生抗体。
Clin Gastroenterol Hepatol. 2022 Feb;20(2):465-467.e2. doi: 10.1016/j.cgh.2021.01.006. Epub 2021 Jan 6.
9
Immunogenicity of biologic agents in rheumatology.风湿学中的生物制剂的免疫原性。
Nat Rev Rheumatol. 2021 Feb;17(2):81-97. doi: 10.1038/s41584-020-00540-8. Epub 2020 Dec 14.
10
Effect of IBD medications on COVID-19 outcomes: results from an international registry.IBD 药物对 COVID-19 结局的影响：来自国际注册研究的结果。
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.
Zotero 插件